Insight Molecular Diagnostics Change in Accounts Receivable 2014-2025 | IMDX

Insight Molecular Diagnostics change in accounts receivable from 2014 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

Insight Molecular Diagnostics Change in Accounts Receivable 2014-2025 | IMDX

Insight Molecular Diagnostics change in accounts receivable from 2014 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
Veeva Systems (VEEV)$46.1B
Tempus AI (TEM)$13.6B
Doximity (DOCS)$12.3B
Hims & Hers Health (HIMS)$10.2B
IRhythm Technologies (IRTC)$5.1B
Hinge Health (HNGE)$4.6B
Privia Health (PRVA)$2.6B
Inspire Medical Systems (INSP)$2.6B
Heartflow (HTFL)$2.4B
Phreesia (PHR)$1.7B
Enovis (ENOV)$1.7B
10x Genomics (TXG)$1.7B
Schrodinger (SDGR)$1.5B
Omnicell (OMCL)$1.5B
Azenta (AZTA)$1.4B
Clover Health Investments (CLOV)$1.3B
Claritev (CTEV)$1.2B
Evolent Health (EVH)$1.1B
Fulgent Genetics (FLGT)$659M
Zepp Health (ZEPP)$630M
Veradigm (MDRX)$503M
Standard BioTools (LAB)$482M
Talkspace (TALK)$435M
Butterfly Network (BFLY)$363M
Carlsmed (CARL)$349M
TruBridge (TBRG)$290M
Outset Medical (OM)$243M
SOPHiA GENETICS SA (SOPH)$236M
Nyxoah SA (NYXH)$224M
Health Catalyst (HCAT)$211M